Published in Infect Immun on February 05, 2007
Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol (2010) 3.45
Horizontal gene transfer of the secretome drives the evolution of bacterial cooperation and virulence. Curr Biol (2009) 2.35
Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol (2011) 2.15
Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol (2012) 1.86
Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol (2008) 1.57
Probiotics: properties, examples, and specific applications. Cold Spring Harb Perspect Med (2013) 1.28
Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med (2013) 1.17
Probiotics, enteric and diarrheal diseases, and global health. Gastroenterology (2010) 1.16
'Gut health': a new objective in medicine? BMC Med (2011) 1.15
Bacteria regulate intestinal epithelial cell differentiation factors both in vitro and in vivo. PLoS One (2013) 1.13
Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med (2010) 1.11
Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients (2013) 1.08
No vacancy: how beneficial microbes cooperate with immunity to provide colonization resistance to pathogens. J Immunol (2015) 1.05
Nonpathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells. Infect Immun (2007) 1.02
The dietary histone deacetylase inhibitor sulforaphane induces human beta-defensin-2 in intestinal epithelial cells. Immunology (2008) 1.02
Innate immune signaling in defense against intestinal microbes. Immunol Rev (2012) 1.00
Discovering probiotic microorganisms: in vitro, in vivo, genetic and omics approaches. Front Microbiol (2015) 0.97
Probiotics and gastrointestinal infections. Interdiscip Perspect Infect Dis (2009) 0.96
The K5 capsule of Escherichia coli strain Nissle 1917 is important in mediating interactions with intestinal epithelial cells and chemokine induction. Infect Immun (2009) 0.93
On the physiology and pathophysiology of antimicrobial peptides. Mol Med (2008) 0.93
Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host. Infect Immun (2010) 0.92
Differential induction of antimicrobial REGIII by the intestinal microbiota and Bifidobacterium breve NCC2950. Appl Environ Microbiol (2013) 0.92
Probiotic/synbiotic therapy for treating critically ill patients from a gut microbiota perspective. Dig Dis Sci (2012) 0.90
Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science. Antiinflamm Antiallergy Agents Med Chem (2009) 0.89
Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. J Invest Dermatol (2008) 0.88
TcpC protein from E. coli Nissle improves epithelial barrier function involving PKCζ and ERK1/2 signaling in HT-29/B6 cells. Mucosal Immunol (2013) 0.88
Probiotics, nuclear receptor signaling, and anti-inflammatory pathways. Gastroenterol Res Pract (2011) 0.88
A Longitudinal Study of the Feline Faecal Microbiome Identifies Changes into Early Adulthood Irrespective of Sexual Development. PLoS One (2015) 0.85
Interference of Bifidobacterium choerinum or Escherichia coli Nissle 1917 with Salmonella Typhimurium in gnotobiotic piglets correlates with cytokine patterns in blood and intestine. Clin Exp Immunol (2010) 0.84
Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World J Gastroenterol (2016) 0.83
Activation of Immune and Defense Responses in the Intestinal Mucosa by Outer Membrane Vesicles of Commensal and Probiotic Escherichia coli Strains. Front Microbiol (2016) 0.83
Differential Effects of Escherichia coli Nissle and Lactobacillus rhamnosus Strain GG on Human Rotavirus Binding, Infection, and B Cell Immunity. J Immunol (2016) 0.83
Interactions between Innate Immunity, Microbiota, and Probiotics. J Immunol Res (2015) 0.82
Actual concept of "probiotics": is it more functional to science or business? World J Gastroenterol (2013) 0.82
Escherichia coli Nissle 1917 bacterial ghosts retain crucial surface properties and express chlamydial antigen: an imaging study of a delivery system for the ocular surface. Drug Des Devel Ther (2015) 0.81
Effect of yoghurt containing Bifidobacterium lactis Bb12® on faecal excretion of secretory immunoglobulin A and human beta-defensin 2 in healthy adult volunteers. Nutr J (2011) 0.81
Diet therapy for inflammatory bowel diseases: The established and the new. World J Gastroenterol (2016) 0.80
Antimicrobial Human β-Defensins in the Colon and Their Role in Infectious and Non-Infectious Diseases. Pathogens (2013) 0.80
How bacteria-induced apoptosis of intestinal epithelial cells contributes to mucosal inflammation. Int J Inflam (2010) 0.79
Escherichia coli Nissle 1917 protects gnotobiotic pigs against human rotavirus by modulating pDC and NK-cell responses. Eur J Immunol (2016) 0.79
Dextran sodium sulfate-induced inflammation alters the expression of proteins by intestinal Escherichia coli strains in a gnotobiotic mouse model. Appl Environ Microbiol (2011) 0.79
Escherichia coli Nissle 1917 enhances bioavailability of serotonin in gut tissues through modulation of synthesis and clearance. Sci Rep (2015) 0.79
Structural bacterial molecules as potential candidates for an evolution of the classical concept of probiotics. Adv Nutr (2011) 0.77
A question of survival? Interaction between probiotics and the gastrointestinal tract. Wien Klin Wochenschr (2007) 0.76
Comparative secretome analysis of four isogenic Bacillus clausii probiotic strains. Proteome Sci (2013) 0.76
Disruption of Escherichia coli Nissle 1917 K5 capsule biosynthesis, through loss of distinct kfi genes, modulates interaction with intestinal epithelial cells and impact on cell health. PLoS One (2015) 0.76
Flagellin Induces β-Defensin 2 in Human Colonic Ex vivo Infection with Enterohemorrhagic Escherichia coli. Front Cell Infect Microbiol (2016) 0.75
Intestinal Epithelial Cell Regulation of Adaptive Immune Dysfunction in Human Type 1 Diabetes. Front Immunol (2017) 0.75
Interleukin-8, CXCL1, and MicroRNA miR-146a Responses to Probiotic Escherichia coli Nissle 1917 and Enteropathogenic E. coli in Human Intestinal Epithelial T84 and Monocytic THP-1 Cells after Apical or Basolateral Infection. Infect Immun (2016) 0.75
The Interplay between Defensins and Microbiota in Crohn's Disease. Mediators Inflamm (2017) 0.75
Outer Membrane Vesicles and Soluble Factors Released by Probiotic Escherichia coli Nissle 1917 and Commensal ECOR63 Enhance Barrier Function by Regulating Expression of Tight Junction Proteins in Intestinal Epithelial Cells. Front Microbiol (2016) 0.75
The level of beta defensin-2 in saliva and its expression in parotid gland epithelial cells after probiotic (Lactobacillus reuteri) induction to inhibit Streptococcus mutans in caries. Eur J Dent (2017) 0.75
Propionibacterium freudenreichii Surface Protein SlpB Is Involved in Adhesion to Intestinal HT-29 Cells. Front Microbiol (2017) 0.75
Colonization by non-pathogenic bacteria alters mRNA expression of cytochromes P450 in originally germ-free mice. Folia Microbiol (Praha) (2017) 0.75
One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A (2000) 96.90
Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature (2004) 14.80
Genetic analysis of Escherichia coli biofilm formation: roles of flagella, motility, chemotaxis and type I pili. Mol Microbiol (1998) 10.07
Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol (2001) 6.62
Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology (2004) 6.47
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (1999) 5.36
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 5.34
Flagellin-deficient Legionella mutants evade caspase-1- and Naip5-mediated macrophage immunity. PLoS Pathog (2006) 5.17
Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology (2001) 4.44
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 4.40
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut (2004) 3.80
Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J Clin Invest (1995) 3.78
A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA (1994) 3.66
Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol (1999) 3.39
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther (1997) 3.02
Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol (1999) 2.93
Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol (2004) 2.80
Functional food science and gastrointestinal physiology and function. Br J Nutr (1998) 2.78
Naip5 affects host susceptibility to the intracellular pathogen Legionella pneumophila. Curr Biol (2003) 2.55
NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun (2004) 2.47
Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr (1995) 2.30
Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology (2002) 2.19
NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem (2005) 2.06
The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance(s) active in vitro and in vivo. Appl Environ Microbiol (1997) 2.03
Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci (1995) 1.99
Enteroaggregative Escherichia coli expresses a novel flagellin that causes IL-8 release from intestinal epithelial cells. J Clin Invest (2000) 1.96
Flagellin of enteropathogenic Escherichia coli stimulates interleukin-8 production in T84 cells. Infect Immun (2003) 1.49
Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther (2003) 1.40
Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol (2004) 1.32
The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol (2004) 1.31
Salmonella enteritidis FliC (flagella filament protein) induces human beta-defensin-2 mRNA production by Caco-2 cells. J Biol Chem (2001) 1.27
Health benefits of probiotics. Br J Nutr (1998) 1.27
Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol Neonate (1997) 1.20
Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun (2005) 1.15
Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr Infect Dis J (2002) 1.14
Variation in bacterial flagellins: from sequence to structure. Trends Microbiol (2006) 1.13
Genomic peculiarity of coding sequences and metabolic potential of probiotic Escherichia coli strain Nissle 1917 inferred from raw genome data. J Biotechnol (2005) 1.11
Probiotics in human disease. Am J Clin Nutr (2001) 1.08
Pre-, pro- and synbiotics. Curr Opin Clin Nutr Metab Care (2001) 0.96
The consumption of two new probiotic strains, Lactobacillus gasseri CECT 5714 and Lactobacillus coryniformis CECT 5711, boosts the immune system of healthy humans. Int Microbiol (2006) 0.96
Oral administration of probiotic Escherichia coli after birth reduces frequency of allergies and repeated infections later in life (after 10 and 20 years). Int Arch Allergy Immunol (2003) 0.95
Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children. Medicina (B Aires) (2003) 0.93
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun (2004) 2.47
Human α-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. Science (2012) 2.44
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature (2011) 2.31
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology (2002) 2.15
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2003) 2.06
NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem (2005) 2.06
Genetic structure and distribution of the colibactin genomic island among members of the family Enterobacteriaceae. Infect Immun (2009) 1.93
Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol (2009) 1.88
Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis (2002) 1.80
The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol (2007) 1.73
Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol (2006) 1.73
Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol (2003) 1.72
Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol (2002) 1.59
Inflammatory Bowel Disease. Dtsch Arztebl Int (2016) 1.56
Mitochondrial gene polymorphisms that protect mice from colitis. Gastroenterology (2013) 1.53
Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology (2012) 1.39
The expression patterns of peritoneal defensins. Perit Dial Int (2007) 1.39
[Suspected cases of severe side effects after infliximab (Remicade) in Germany]. Med Klin (Munich) (2003) 1.38
The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol (2004) 1.31
Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol (2007) 1.31
Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation (2008) 1.30
Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A (2010) 1.29
Paneth's disease. J Crohns Colitis (2010) 1.29
Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol (2005) 1.27
Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol (2004) 1.26
Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr Opin Gastroenterol (2007) 1.25
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One (2009) 1.24
Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol (2006) 1.21
Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med (2013) 1.17
Defensins and cathelicidins in gastrointestinal infections. Curr Opin Gastroenterol (2007) 1.16
Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J Leukoc Biol (2007) 1.14
Bacteria regulate intestinal epithelial cell differentiation factors both in vitro and in vivo. PLoS One (2013) 1.13
Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut (2007) 1.11
Role of fibronectin in curli-mediated internalization. FEMS Microbiol Lett (2002) 1.07
A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. J Microbiol Methods (2005) 1.05
From intestinal stem cells to inflammatory bowel diseases. World J Gastroenterol (2011) 1.03
Antibacterial activity of human defensins on anaerobic intestinal bacterial species: a major role of HBD-3. Microbes Infect (2009) 1.03
Olfactomedin-4 is a glycoprotein secreted into mucus in active IBD. J Crohns Colitis (2011) 1.03
Defective paneth cell-mediated host defense in pediatric ileal Crohn's disease. Am J Gastroenterol (2009) 0.97
Crohn's disease--defect in innate defence. World J Gastroenterol (2008) 0.97
The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease. Am J Pathol (2010) 0.96
Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers. J Lipid Res (2005) 0.96
Innate antimicrobial host defense in small intestinal Crohn's disease. Int J Med Microbiol (2009) 0.96
E. coli Nissle 1917 Affects Salmonella adhesion to porcine intestinal epithelial cells. PLoS One (2011) 0.94
Reduced ileal expression of OSTalpha-OSTbeta in non-obese gallstone disease. J Lipid Res (2008) 0.94
Both alpha-haemolysin determinants contribute to full virulence of uropathogenic Escherichia coli strain 536. Microbes Infect (2006) 0.93
Probiotic Escherichia coli Nissle 1917 suppresses allergen-induced Th2 responses in the airways. Int Arch Allergy Immunol (2009) 0.93
Paneth cells and the innate immune response. Curr Opin Gastroenterol (2006) 0.91
Inflammatory bowel disease: an impaired barrier disease. Langenbecks Arch Surg (2012) 0.91
Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2. J Crohns Colitis (2012) 0.90
In vivo gene expression profiling of human intestinal epithelial cells: analysis by laser microdissection of formalin fixed tissues. BMC Genomics (2008) 0.90
Enterobacterial tumor colonization in mice depends on bacterial metabolism and macrophages but is independent of chemotaxis and motility. Int J Med Microbiol (2010) 0.88
Diminished expression of apical sodium-dependent bile acid transporter in gallstone disease is independent of ileal inflammation. Digestion (2008) 0.88
Association of a functional variant in the Wnt co-receptor LRP6 with early onset ileal Crohn's disease. PLoS Genet (2012) 0.88
Thiopurines in inflammatory bowel disease revisited. World J Gastroenterol (2013) 0.88
A novel multiplex-protein array for serum diagnostics of colon cancer: a case-control study. BMC Cancer (2012) 0.87
Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol (2006) 0.86
More than a marine propeller--the flagellum of the probiotic Escherichia coli strain Nissle 1917 is the major adhesin mediating binding to human mucus. Int J Med Microbiol (2012) 0.86